StreetInsider.com News Articles

Rigel Pharmaceuticals (RIGL) Tops Q4 EPS by 1354c

Tue, 03 Mar 2026 16:22:51 -0500

Rigel Pharmaceuticals (NASDAQ: RIGL) reported Q4 EPS of $13.54. Revenue for the quarter came in at $69.8 million.

For earnings history and earnings-related data on Rigel Pharmaceuticals (RIGL) click here.

Form 8-K RIGEL PHARMACEUTICALS For: Mar 03

Tue, 03 Mar 2026 16:14:00 -0500

si-local-file:///var/storage/secattach/20260303/26101474.html

Form 8-K RIGEL PHARMACEUTICALS For: Mar 03

Tue, 03 Mar 2026 16:14:00 -0500

si-local-file:///var/storage/secattach/20260303/26101474.html

Form 10-K RIGEL PHARMACEUTICALS For: Dec 31

Tue, 03 Mar 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260303/26101333.html

Form 10-K RIGEL PHARMACEUTICALS For: Dec 31

Tue, 03 Mar 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20260303/26101333.html

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Tue, 03 Mar 2026 16:01:00 -0500

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million
Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit
Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and